A radiomics‐based nomogram may be useful for predicting telomerase reverse transcriptase promoter mutation status in adult glioblastoma

Abstract

AbstractBackground and purposeAs a crucial diagnostic and prognostic biomarker, telomerase reverse transcriptase (TERT) promoter mutation holds immense significance for personalized treatment of patients with glioblastoma (GBM). In this study, we developed a radiomics nomogram to determine the TERT promoter mutation status and assessed its prognostic efficacy in GBM patients.MethodsThe study retrospectively included 145 GBM patients. A comprehensive set of 3736 radiomics features was extracted from preoperative magnetic resonance imaging, including T2‐weighted imaging, T1‐weighted imaging (T1WI), contrast‐enhanced T1WI, and fluid‐attenuated inversion recovery. The construction of the radiomics model was based on integrating the radiomics signature (rad‐score)with clinical features. Receiver‐operating characteristic curve analysis was employed to evaluate the discriminative ability of the prediction model, and the risk score was used to stratify patient outcomes.ResultsThe least absolute shrinkage and selection operator classifier identified 10 robust features for constructing the prediction model, and the radiomics nomogram exhibited excellent performance in predicting TERT promoter mutation status, with area under the curve values of.906 (95% confidence interval [CI]:.850–.963) and.899 (95% CI:.708–.966) in the training and validation sets, respectively. The clinical utility of the radiomics nomogram is further supported by calibration curve and decision curve analyses. Additionally, the radiomics nomogram effectively stratified GBM patients with significantly different prognoses (HR = 1.767, p = .019).ConclusionThe radiomics nomogram holds promise as a modality for evaluating TERT promoter mutations and prognostic outcomes in patients with GBM.